Top Story Today
Novartis Bets $2 Billion That the PI3K Inhibitor Curse Is Broken
Novartis is paying $2 billion upfront (with another $1 billion in milestones) to acquire Synnovation Therapeutics' SNV4818, a next-generation PI3K-alpha inhibitor still in Phase 1/2 trials. The drug class has been a tolerability disaster for over a decade; even Novartis' own Piqray saw one in four patients drop out from side effects. The difference this time: SNV4818 targets only the mutated version of PI3K-alpha found in tumors, leaving healthy cells alone. About 40% of HR+/HER2- breast cancer patients carry the relevant mutation, making the addressable market enormous.
Why it matters: A $2 billion upfront bet on a historically toxic drug class signals that Big Pharma believes precision-targeted redesigns can resurrect failed approaches, and it reshapes the competitive landscape where Relay, Lilly, and Roche are already racing with their own next-gen candidates.
Read more →Clinical Setbacks
Myostatin's Two-Decade Losing Streak Gets Another Entry
Genentech killed its anti-myostatin antibody emugrobart after Phase 2 trials showed no meaningful improvements in muscle growth or motor function for two rare muscle-wasting diseases. No myostatin inhibitor has ever earned FDA approval for anything, despite decades of effort. The bigger question: if emugrobart can't build muscle when muscle loss is the primary problem, can it really preserve muscle during GLP-1-driven weight loss? A separate obesity trial is still running.
Read more →Gilead Walks Away From an HBV Drug It Could Have Owned
The world's biggest liver disease company declined its option on Assembly Biosciences' Phase 1b hepatitis B drug ABI-4334, returning $330 million in potential milestones. With roughly 50 companies chasing an HBV cure and GSK's bepirovirsen hitting Phase 3 endpoints, Gilead apparently decided a Phase 1b capsid assembly modulator wasn't differentiated enough to keep.
Read more →Devices and Safety
A Surgical Robot Told Surgeons the Staples Fired. They Hadn't.
Intuitive Surgical recalled stapler cartridges for its da Vinci robot after one patient death and four serious injuries. The system falsely confirmed that staple lines fired completely, leaving blood vessels cut but unsealed. The FDA is reviewing the issue, which is currently classified as an Early Alert with no formal recall classification yet assigned, and the incident raises uncomfortable questions about post-market monitoring for robotic surgery accessories.
Read more →People and Strategy
Eric Topol Just Joined Biotech's Most Prolific Company Factory
Eric Topol, one of medicine's most cited researchers and its loudest AI evangelist, signed on as an advisor to Flagship Pioneering's Preemptive Health Initiative. The firm behind Moderna is assembling an AI-driven constellation of companies focused on predicting disease before it starts. Adding Topol signals that Flagship's prevention bet is moving from philosophy to execution.
Read more →